Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from ProQR ( (PRQR) ).
On February 9, 2026, ProQR Therapeutics announced planned changes to its board of directors, with co-founder Dinko Valerio and director Alison Lawton set to rotate off the board at the company’s 2026 Annual General Meeting as their terms conclude. The company has hired an executive search firm to identify new board candidates, positioning its governance structure to better support the progression of its clinical programs and long-term value creation.
The move reflects ProQR’s ongoing succession planning efforts and its focus on maintaining a board with the right mix of skills and experience as it advances its Axiomer-based RNA editing pipeline. These changes, following the appointment of two new board members in the last three years, underscore the firm’s emphasis on corporate governance as it seeks to strengthen its strategic execution and stakeholder alignment.
The most recent analyst rating on (PRQR) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on ProQR stock, see the PRQR Stock Forecast page.
Spark’s Take on PRQR Stock
According to Spark, TipRanks’ AI Analyst, PRQR is a Neutral.
ProQR’s overall stock score is primarily impacted by its financial performance and technical analysis. The company’s significant financial challenges, particularly in profitability and cash flow, are the most critical factors. Technical indicators suggest bearish momentum, and the valuation reflects ongoing losses. These factors collectively contribute to a lower overall stock score.
To see Spark’s full report on PRQR stock, click here.
More about ProQR
ProQR Therapeutics N.V. is a clinical-stage biotechnology company focused on developing transformative RNA therapies using its proprietary Axiomer RNA base editing platform. The company aims to harness the body’s own ADAR editing machinery to make precise single-nucleotide edits in RNA, targeting both rare and more prevalent diseases with significant unmet medical need.
Average Trading Volume: 513,084
Technical Sentiment Signal: Sell
Current Market Cap: $158M
Learn more about PRQR stock on TipRanks’ Stock Analysis page.